The highly active, oral fluoropyrimidine capecitabine (Xeloda®: F Hoffmann-La Roche, Basel, Switzerland) was rationally developed to deliver 5-FU preferentially to tumours by exploiting the high concentrations of thymidine phosphorylase in tumour tissue. The gene discussed is TYMP; the disease is neoplasm.